Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD

Chest
M Cazzola, R Dahl

Abstract

Long-acting beta(2)-agonists (LABAs) have been shown to be effective first-line bronchodilators in the treatment of COPD patients, and inhaled corticosteroids (ICSs) have been shown to reduce the frequency and/or severity of exacerbations in COPD patients. The concomitant use of a LABA and an ICS can influence both airway obstruction (ie, smooth muscle contraction, increased cholinergic tone, and loss of elastic recoil), and airway inflammation (ie, increased numbers of neutrophils, macrophages, and CD8+ lymphocytes, elevated interleukin-8 and tumor necrosis factor-alpha levels, and protease/antiprotease imbalance). They are also able to reduce the total number of bacteria adhering to the respiratory mucosa in a concentration-dependent manner without altering the bacterial tropism for mucosa, and to preserve ciliated cells. Several clinical trials support the concept of inhaled combination therapy with LABAs and corticosteroids in stable COPD patients. This type of therapy not only improves airflow obstruction but also provides clinical benefits, as manifested by sustained reduction in overall symptoms, improvements in health-related quality of life, and reductions in exacerbations. All of these effects are very important becau...Continue Reading

References

Aug 1, 1992·The American Review of Respiratory Disease·A B ThompsonS I Rennard
Jul 1, 1991·Agents and Actions·D A LomasR A Stockley
Feb 1, 1996·American Journal of Respiratory and Critical Care Medicine·C G Llewellyn-JonesR A Stockley
May 1, 1996·American Journal of Respiratory and Critical Care Medicine·A WoolcockL A Jacques
Oct 1, 1996·Clinical and Experimental Immunology·L OttonelloF Dallegri
Feb 1, 1997·American Journal of Respiratory and Critical Care Medicine·V M KeatingsP J Barnes
May 1, 1997·American Journal of Respiratory and Critical Care Medicine·P ChanezJ Bousquet
Jun 1, 1997·Pulmonary Pharmacology & Therapeutics·M CazzolaM G Matera
Nov 5, 1998·The Journal of Allergy and Clinical Immunology·P J Barnes
Nov 17, 1998·American Journal of Respiratory and Critical Care Medicine·E PizzichiniF E Hargreave
Apr 20, 1999·Chest·D A MahlerW H Anderson
Nov 11, 1999·American Journal of Respiratory and Critical Care Medicine·S V CulpittP J Barnes
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·P M Calverley
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·P J Barnes
Mar 8, 2000·Respiration; International Review of Thoracic Diseases·F YildizO Ozkarakaş
Jul 27, 2000·The New England Journal of Medicine·P J Barnes
Nov 25, 2000·Trends in Endocrinology and Metabolism : TEM·R J Borski
Jan 3, 2001·The New England Journal of Medicine·UNKNOWN Lung Health Study Research GroupMelissa Skeans
May 24, 2001·American Journal of Respiratory and Critical Care Medicine·M SaettaL M Fabbri
Aug 14, 2001·American Journal of Respiratory and Critical Care Medicine·A O'BrienS Rounds
Aug 25, 2001·American Journal of Respiratory and Critical Care Medicine·D D Sin, J V Tu
Sep 11, 2001·American Journal of Respiratory and Critical Care Medicine·R DahlUNKNOWN Formoterol in Chronic Obstructive Pulmonary Disease I Study Group
Nov 24, 2001·American Journal of Respiratory and Critical Care Medicine·T SeemungalJ A Wedzicha
Nov 12, 2002·American Journal of Respiratory and Critical Care Medicine·Leonardo M FabbriAlberto Papi

❮ Previous
Next ❯

Citations

May 5, 2004·Pulmonary Pharmacology & Therapeutics·M CazzolaS Centanni
Dec 23, 2006·American Journal of Respiratory and Critical Care Medicine·Tanyalak ParimonDavid H Au
Dec 1, 2007·International Journal of Chronic Obstructive Pulmonary Disease·Erkan Ceylan
Nov 30, 2007·International Journal of Chronic Obstructive Pulmonary Disease·Mario Cazzola, Nicola A Hanania
Feb 12, 2011·International Journal of Chronic Obstructive Pulmonary Disease·Richard RussellIdelle Weisman
May 14, 2009·International Journal of Chronic Obstructive Pulmonary Disease·Carl LlorUNKNOWN BRAMOX Study Group
Dec 9, 2014·Expert Review of Respiratory Medicine·Maria Gabriella MateraMario Cazzola
Oct 22, 2013·Expert Opinion on Pharmacotherapy·Mario CazzolaMaria Gabriella Matera
Feb 18, 2012·Expert Opinion on Emerging Drugs·Maria Gabriella MateraMario Cazzola
Aug 25, 2012·Expert Opinion on Investigational Drugs·Mario CazzolaMaria Gabriella Matera
Apr 12, 2007·Expert Opinion on Pharmacotherapy·Sabina A AntoniuClaudio F Donner
Sep 28, 2007·Trends in Pharmacological Sciences·Mario CazzolaClive Page
Dec 20, 2005·Pulmonary Pharmacology & Therapeutics·Giovanni A RossiMario Cazzola
Jun 21, 2005·Pulmonary Pharmacology & Therapeutics·Mario Cazzola
Nov 2, 2005·Expert Opinion on Pharmacotherapy·Stefano Centanni, Fabiano Di Marco
Apr 16, 2008·European Journal of Pharmacology·Hadi SarirGert Folkerts
Aug 9, 2008·Respiratory Medicine·Mario CazzolaStephen Rennard
Apr 3, 2012·Current Opinion in Pharmacology·Anders BjergJan Lötvall
Oct 4, 2005·Respiratory Medicine·Douglas W MapelFloyd J Frost
Sep 30, 2016·NPJ Primary Care Respiratory Medicine·Barbara P YawnAndrea Rossi
Jun 25, 2008·Chest·Bartolome R Celli
Jan 28, 2010·Expert Opinion on Pharmacotherapy·Mario CazzolaMaria G Matera
May 8, 2014·Expert Review of Respiratory Medicine·Eric D BatemanDonald Banerji
May 23, 2012·Pharmacological Reviews·Mario CazzolaM Gabriella Matera
Jul 1, 2020·Expert Review of Clinical Pharmacology·Luigino CalzettaMario Cazzola
Sep 12, 2019·F1000Research·Mario CazzolaMaria Gabriella Matera

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.